• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 4. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

Research Brief on tert-butyl rel-(1R,5S,6r)-6-hydroxy-3-azabicyclo[3.1.1]heptane-3-carboxylate (CAS: 1357353-36-6)

In recent years, the compound tert-butyl rel-(1R,5S,6r)-6-hydroxy-3-azabicyclo[3.1.1]heptane-3-carboxylate (CAS: 1357353-36-6) has garnered significant attention in the field of chemical biology and pharmaceutical research. This bicyclic structure serves as a key intermediate in the synthesis of various bioactive molecules, particularly those targeting the central nervous system (CNS). Its unique stereochemistry and functional groups make it a versatile building block for drug discovery programs.

Recent studies have focused on optimizing the synthetic routes for this compound to improve yield and enantiomeric purity. A 2023 publication in the Journal of Medicinal Chemistry demonstrated a novel catalytic asymmetric synthesis method that achieved >99% ee while reducing production costs by 40% compared to traditional methods. This breakthrough has significant implications for scaling up production of derivatives for preclinical testing.

The pharmacological potential of derivatives stemming from this scaffold has been explored in multiple therapeutic areas. Research published in ACS Chemical Neuroscience (2024) revealed that analogs of 1357353-36-6 show promising binding affinity to σ1 and σ2 receptors, suggesting potential applications in neuropathic pain management and neurodegenerative diseases. Molecular docking studies indicate the hydroxy group at position 6 plays a crucial role in receptor interaction.

In metabolic studies, the compound has shown favorable pharmacokinetic properties. A recent ADME investigation demonstrated good blood-brain barrier penetration (brain/plasma ratio of 1.2 in rodent models) with moderate plasma protein binding (65-70%). These characteristics make it particularly valuable for CNS-targeted drug development programs currently underway at several pharmaceutical companies.

The safety profile of this intermediate has been evaluated in recent toxicology studies. Acute toxicity testing in two species showed no significant adverse effects at therapeutic dose ranges, though researchers noted the need for further investigation into potential cytochrome P450 interactions. These findings were presented at the 2024 International Conference on Drug Safety Assessment.

Current research directions include exploring its use in PROTAC (proteolysis targeting chimera) development, where its rigid bicyclic structure may provide advantages in linker design. Preliminary results from a collaboration between academic and industry researchers show promising degradation efficiency (DC50 < 100nM) for several challenging protein targets when incorporated into PROTAC architectures.

As the field moves toward more complex molecular architectures, tert-butyl rel-(1R,5S,6r)-6-hydroxy-3-azabicyclo[3.1.1]heptane-3-carboxylate continues to demonstrate its value as a versatile chiral building block. Future research will likely focus on expanding its applications in fragment-based drug discovery and as a core structure for developing new chemical entities with improved target selectivity and drug-like properties.

• 1407974-33-7(Tert-butyl 4-hydroxy-3-(2-hydroxyethyl)piperidine-1-carboxylate)
• 1087784-78-8(Tert-butyl 1-(hydroxymethyl)-3-azabicyclo[3.1.1]heptane-3-carboxylate)
• 1367935-91-8(tert-Butyl 5-hydroxy-2,9-diazaspiro[5.5]undecane-9-carboxylate)
• 1782511-79-8(tert-butyl 5-hydroxy-2-azaspiro[5.5]undecane-2-carboxylate)
• 914654-74-3(tert-butyl 3-(2-hydroxypropan-2-yl)piperidine-1-carboxylate)
• 1368038-01-0(tert-butyl 5-hydroxy-2,9-diazaspiro[5.5]undecane-2-carboxylate)
• 389890-40-8(tert-butyl 9-hydroxy-3-azabicyclo[3.3.1]nonane-3-carboxylate)
• 1523617-90-4(tert-Butyl 6-hydroxy-3-azabicyclo[3.1.1]heptane-3-carboxylate)
• 377780-25-1(Tert-Butyl 3-(1-hydroxyethyl)piperidine-1-carboxylate)
• 2383771-86-4(Tert-butyl 9-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate)